Pompe disease

Showing 5 posts of 5 posts found.

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

August 17, 2023
Medical Communications Amicus Therapeutics, MHRA, NICE, Pompe disease, Rare Diseases

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorisation …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

May 3, 2023
Sales and Marketing License Agreement, Pompe disease, Rare Diseases, Sanofi, maze therapeutics, treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement for Maze’s gluogen synthase 1 …


Sanofi Genzyme present positive Phase 2 results for fatal neuromuscular disease treatment

March 4, 2016
Medical Communications, Research and Development Pompe disease, Sanofi, clinical trial, neuromuscular, phase 2

Sanofi Genzyme, the branch of the French-based pharma company that focuses on diseases difficult to diagnose and treat, have published …

Genzyme plans new Belgium facility

January 25, 2011
Manufacturing and Production Belgium, Genzyme, Lumizyme, Myozyme, Pompe disease, Sanofi-Aventis, alglucosidase alfa

US rare disease drug specialist Genzyme, the subject of a hostile takeover offer from France’s Sanofi-Aventis, says that it will …

FDA approves Genzyme’s Lumizyme

May 27, 2010
Sales and Marketing Genzyme, Lumizyme, Myozyme, Pompe disease

US biotech Genzyme is celebrating FDA approval of its late-onset treatment for Pompe disease Lumizyme. The green light to market …

Latest content